Handel nachbörslich: 1.57

Spero Therapeutics Inc (SPRO)

Spero Therapeutics Inc Aktie (SPRO) Neueste Nachrichten

Spero Therapeutics Inc (SPRO)

Spero Therapeutics Inc Aktie (SPRO) Neueste Nachrichten

Spero Therapeutics to Participate in H.C. Wainwright Annual - GlobeNewswire

Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference

HC Wainwright Reaffirms Buy Rating for Spero Therapeutics (NASDAQ:SPRO) - MarketBeat

Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update - Yahoo Finance

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates

Spero Therapeutics (SPRO) Set to Announce Earnings on Wednesday - Defense World

Investors in Spero Therapeutics (NASDAQ:SPRO) have unfortunately lost 90% over the last three years - Yahoo New Zealand News

Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Lifestyle Australia

Spero Therapeutics, Inc. (SPRO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Movies UK

Spero Therapeutics (SPRO) Sees Hammer Chart Pattern: Time to Buy? - Yahoo News UK

Shareholders in Spero Therapeutics (NASDAQ:SPRO) are in the red if they invested three years ago - Yahoo Finance

Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates

Spero Therapeutics (SPRO) to Release Quarterly Earnings on Wednesday - MarketBeat

Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May ... - GlobeNewswire

Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024

Investors in Spero Therapeutics (NASDAQ:SPRO) from three years ago are still down 88%, even after 12% gain this past week - Simply Wall St

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Spero Therapeutics Delivers On Game Plan To Create Shareholder Value (NASDAQ:SPRO) - Seeking Alpha

14 Cheap Penny Stocks to Buy According to Analysts - Insider Monkey

ALPMY: 3 Affordable Pharma Stocks to Buy for Portfolio Gains - StockNews.com

Spero Therapeutics, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - Yahoo Finance

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2023 Earnings Call Transcript March 13, 2024 - Yahoo Finance

Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Why Robinhood Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates

Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update

Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates - Zacks Investment Research

Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27% - Simply Wall St

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on ... - Yahoo Finance

Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections

Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections - GlobeNewswire

Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare Conference

Have Insiders Sold Spero Therapeutics Shares Recently? - Simply Wall St

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

JNJ: Top 4 Pharma Stocks on the Rise for Potential Gains - StockNews.com

Spero Therapeutics Provides Corporate Update and 2024 Outlook

Spero Therapeutics Provides Corporate Update and 2024 Outlook - GlobeNewswire

Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

SPRO: 3 Pharma Stocks to Buy Before Year-End - StockNews.com

Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update - Yahoo Finance

Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer - GlobeNewswire

Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of ... - Yahoo Finance

Spero Therapeutics: Multi-Asset Pipeline Could Outpace Tebipenem HBr Deal With GSK - Seeking Alpha

PFE: 3 Pharma Stocks Every Investor Should Know - StockNews.com

Spero CEO to step down; new CEO to turn focus toward lung disease antibiotic - Boston Business Journal - The Business Journals

Spero Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire

Down -12.5% in 4 Weeks, Here's Why Spero Therapeutics, Inc. (SPRO) Looks Ripe for a Turnaround - Yahoo New Zealand News

Pear Therapeutics and Spero Health to Expand Access to Prescription Digital Therapeutics for People in Recovery ... - Business Wire

Ähnlich wie SPRO